6th Conference on Retroviruses and Opportunistic Infections Chicago, IL - January 31-February 4, 1999

Conf Retroviruses Opportunistic Infect 1999 Jan 31-Feb 4; 6th:70 (abstract no. 16)

Delehanty J, Wakeford C, Hulett L, Quinn J, McCreedy B, Almond M, Miralles D, Rousseau F
in vitro activity against HIV-1 (EC50 10-20nM) and HBV(EC50 10-40nM). The in vitro activity against HIV-1 is approximately 4-10 fold greater than with 3TC. This phase I/II randomized study evaluated antiviral activity, as measured by plasma HIV RNA over 12 days. Patients were randomized to either 25, 100, 200 mg QD of FTC or 3TC 150 mg BID. HIV RNA was monitored frequently (Amplicor ™ Assay) over the 12-day study period. The study was powered to detect a difference of 0.5 log₁₀ in AAUCMB between FTC 200 mg QD and 3TC 150 mg BID. Eighty-one antiretroviral naïve HIV-infected patients, mean age 32, 47% female, mean CD4 437, mean HIV RNA 4.4 log₁₀, were randomized in the study. FTC at 200 mg QD had a significantly greater antiviral activity than 3TC as measured by AAUCMB over the study period (p= 0.047) or slope of RNA decay over the first week of treatment (p= 0.03). At the end of the study, HIV RNA decreases from baseline were respectively 1.45, 1.48, 1.60, 1.70 log₁₀ for 3TC 150 mg BID, FTC 25, 100 and 200 mg QD. FTC at both 25 and 100 mg QD had similar antiviral activity to 3TC 150 mg BID. Preliminary safety assessment showed that all regimens were well tolerated; two patients developed asymptomatic elevation of CPK in the FTC 200-mg group. The results of this 12-day randomized clinical trial confirm in vitro findings that FTC has superior antiviral activity as compared to 3TC. These results also confirm the potent antiviral activity of FTC as a QD drug. Further confirmatory long-term studies are underway.

Keywords: AEGIS, Lamivudine, HIV, Reverse Transcriptase Inhibitors, Anti-HIV Agents, HIV-1, HIV Infections, HIV Protease Inhibitors, HIV-1 Reverse Transcriptase, Longitudinal Studies, Female, in vitro, Human, pathogenicity, AIDS

1999-01-31
16

Copyright © 1999 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.